Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35).

Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol (2013) 2.30

Hereditary spastic paraplegias: membrane traffic and the motor pathway. Nat Rev Neurosci (2011) 2.30

Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases. J Inherit Metab Dis (2012) 1.66

The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56

Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord (2015) 1.52

Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models. J Lipid Res (2010) 1.31

Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol (2013) 1.20

Neurodegeneration with brain iron accumulation: an overview. Iran J Child Neurol (2014) 1.18

Exome sequencing and SNP analysis detect novel compound heterozygosity in fatty acid hydroxylase-associated neurodegeneration. Eur J Hum Genet (2011) 1.18

Mutations in phospholipase DDHD2 cause autosomal recessive hereditary spastic paraplegia (SPG54). Eur J Hum Genet (2013) 1.09

Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front Pharmacol (2014) 1.09

Delving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosology. Hum Genet (2015) 1.09

Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia (2011) 1.05

Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. Neuropathol Appl Neurobiol (2015) 0.96

The use of next-generation sequencing in movement disorders. Front Genet (2012) 0.94

Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells. Bioorg Med Chem (2010) 0.90

ELOVL5 mutations cause spinocerebellar ataxia 38. Am J Hum Genet (2014) 0.90

Normal fur development and sebum production depends on fatty acid 2-hydroxylase expression in sebaceous glands. J Biol Chem (2011) 0.88

Excess iron harms the brain: the syndromes of neurodegeneration with brain iron accumulation (NBIA). J Neural Transm (Vienna) (2012) 0.88

Stereospecificity of fatty acid 2-hydroxylase and differential functions of 2-hydroxy fatty acid enantiomers. J Lipid Res (2012) 0.87

Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain (2016) 0.87

CYP2U1 mutations in two Iranian patients with activity induced dystonia, motor regression and spastic paraplegia. Eur J Paediatr Neurol (2016) 0.86

Axon-glial interaction in the CNS: what we have learned from mouse models of Pelizaeus-Merzbacher disease. J Anat (2011) 0.84

Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies. Brain (2014) 0.83

2-Hydroxylated sphingomyelin profiles in cells from patients with mutated fatty acid 2-hydroxylase. Lipids Health Dis (2011) 0.82

The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview. J Inherit Metab Dis (2014) 0.82

Human genetic disorders of sphingolipid biosynthesis. J Inherit Metab Dis (2014) 0.81

Defective lipid metabolism in neurodegeneration with brain iron accumulation (NBIA) syndromes: not only a matter of iron. J Inherit Metab Dis (2014) 0.81

2'-Hydroxy ceramide in membrane homeostasis and cell signaling. Adv Biol Regul (2013) 0.80

The Crystal Structure of an Integral Membrane Fatty Acid α-Hydroxylase. J Biol Chem (2015) 0.78

Myelination in the absence of UDP-galactose:ceramide galactosyl-transferase and fatty acid 2 -hydroxylase. BMC Neurosci (2011) 0.78

Gray and white matter alterations in hereditary spastic paraplegia type SPG4 and clinical correlations. J Neurol (2015) 0.77

Loss of hydroxyl groups from the ceramide moiety can modify the lateral diffusion of membrane proteins in S. cerevisiae. J Lipid Res (2014) 0.77

Exome sequencing identifies GCDH (glutaryl-CoA dehydrogenase) mutations as a cause of a progressive form of early-onset generalized dystonia. Hum Genet (2011) 0.77

Phenotypic variability of a likely FA2H founder mutation in a family with complicated hereditary spastic paraplegia. Clin Genet (2013) 0.77

Heterozygous FA2H mutations in autism spectrum disorders. BMC Med Genet (2013) 0.76

A high-throughput resequencing microarray for autosomal dominant spastic paraplegia genes. Neurogenetics (2012) 0.76

Clinical Spectrum of Hereditary Spastic Paraplegia in Children: A study of 74 cases. Sultan Qaboos Univ Med J (2013) 0.75

Phytosphingosine degradation pathway includes fatty acid α-oxidation reactions in the endoplasmic reticulum. Proc Natl Acad Sci U S A (2017) 0.75

Mitochondrial dysfunction and defects in lipid homeostasis as therapeutic targets in neurodegeneration with brain iron accumulation. Rare Dis (2016) 0.75

Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01

Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62

SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55

Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol (2008) 3.49

Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23

DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03

A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol (2008) 3.00

PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet (2002) 2.81

The identification of a conserved domain in both spartin and spastin, mutated in hereditary spastic paraplegia. Genomics (2003) 2.69

Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet (2004) 2.50

Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol (2010) 2.48

ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47

Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet (2004) 2.45

Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nat Genet (2009) 2.32

SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet (2002) 2.27

Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta (2008) 2.22

Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet (2009) 2.22

Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry (2012) 2.20

Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17

Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet (2007) 2.09

Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09

Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet (2010) 2.08

Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02

3D analysis of facial morphology. Am J Med Genet A (2004) 1.95

Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem (2010) 1.93

Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain (2013) 1.93

Mutations in the autoregulatory domain of β-tubulin 4a cause hereditary dystonia. Ann Neurol (2013) 1.90

Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol (2013) 1.88

α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75

Towards a complete resolution of the genetic architecture of disease. Trends Genet (2010) 1.75

A novel α-synuclein missense mutation in Parkinson disease. Neurology (2013) 1.74

Evolutionarily assembled cis-regulatory module at a human ciliopathy locus. Science (2012) 1.74

Loss of function mutations in the gene encoding latent transforming growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma. Hum Mol Genet (2009) 1.74

A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71

KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet (2011) 1.66

Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet (2008) 1.65

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther (2008) 1.59

Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J Biol Chem (2009) 1.58

Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging (2010) 1.56

Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord (2010) 1.56

The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol (2011) 1.55

Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia. Arch Neurol (2003) 1.55

Is the transportation highway the right road for hereditary spastic paraplegia? Am J Hum Genet (2002) 1.53

Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am J Hum Genet (2013) 1.51

Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies. Brain (2010) 1.51

Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations. Dev Med Child Neurol (2013) 1.51

Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain (2012) 1.50

Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet (2005) 1.47

Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet (2003) 1.45

Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron (2013) 1.45

PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology (2012) 1.44

Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J (2013) 1.40

Familial lymphoma in an Omani kindred with identical class II HLA type. Leuk Lymphoma (2008) 1.38

Recent advances in the genetics of cerebellar ataxias. Curr Neurol Neurosci Rep (2012) 1.37

Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia. Am J Hum Genet (2003) 1.34

Exome sequencing in an SCA14 family demonstrates its utility in diagnosing heterogeneous diseases. Neurology (2012) 1.33

Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer (2008) 1.27

Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J Neurosci (2008) 1.24

Kidney sulfatides in mouse models of inherited glycosphingolipid disorders: determination by nano-electrospray ionization tandem mass spectrometry. J Biol Chem (2002) 1.23

Collecting genetic information in primary care: evaluating a new family history tool. Fam Pract (2005) 1.23

Spastin and microtubules: Functions in health and disease. J Neurosci Res (2007) 1.22

Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am J Hum Genet (2013) 1.22

Exome sequencing in Brown-Vialetto-van Laere syndrome. Am J Hum Genet (2010) 1.22

Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am J Hum Genet (2010) 1.21

Craniofacial expression of human and murine TBX22 correlates with the cleft palate and ankyloglossia phenotype observed in CPX patients. Hum Mol Genet (2002) 1.20

The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat Neurosci (2013) 1.19

A mammalian fatty acid hydroxylase responsible for the formation of alpha-hydroxylated galactosylceramide in myelin. Biochem J (2005) 1.18

The family of hepatoma-derived growth factor proteins: characterization of a new member HRP-4 and classification of its subfamilies. Biochem J (2002) 1.18

The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat (2013) 1.17

Human spastin has multiple microtubule-related functions. J Neurochem (2005) 1.16

Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord (2012) 1.15

Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord (2011) 1.15

Collapsin response mediator protein-4 regulates F-actin bundling. Exp Cell Res (2005) 1.14

Mutant COQ2 in multiple-system atrophy. N Engl J Med (2014) 1.14

Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology (2012) 1.11

A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain (2004) 1.11

Human ataxias: a genetic dissection of inositol triphosphate receptor (ITPR1)-dependent signaling. Trends Neurosci (2010) 1.10

Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. Acta Neuropathol Commun (2014) 1.09

Mapping the brain in younger and older asymptomatic HIV-1 men: frontal volume changes in the absence of other cortical or diffusion tensor abnormalities. Cortex (2011) 1.09

Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry (2013) 1.09

Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol Ther (2009) 1.08